论文部分内容阅读
目的系统评价足量布地奈德溶液雾化治疗对慢性阻塞性肺疾病(COPD)的安全性以及临床应用价值。方法将75例COPD合并急性肺部感染患者随机分为三组:治疗组给予布地奈德雾化吸入治疗2mg/次、3次/d;口服泼尼松龙组给予口服甲泼尼龙片10mg/次,3次/d;对照组不使用任何糖皮质激素。观察三组患者在第二十四、四十八小时和第五天的临床表现、肺功能和动脉血气变化以及副作用情况。结果治疗后症状评分明显改善,肺功能和动脉血气变化程度与对照组比较差异有统计学意义(P<0.05),但治疗组之间差异无统计学意义,与对照组比较,肺功能FEV1均无明显提高(P>0.05)。结论布地奈德溶液雾化吸入对COPD合并急性肺部感染患者可以有效改善自觉症状及生活质量,有良好依从性和安全性。
Objective To evaluate the safety and clinical value of adequate budesonide solution nebulization for chronic obstructive pulmonary disease (COPD). Methods A total of 75 COPD patients with acute pulmonary infection were randomly divided into three groups: the treatment group received budesonide inhalation therapy 2mg / time, 3 times / d; oral prednisolone group given oral methylprednisolone tablets 10mg / Times, 3 times / d; control group did not use any glucocorticoid. The clinical manifestations, pulmonary function and arterial blood gas changes and the side effects of the three groups at the 24th, 48th and the 5th day were observed. Results After treatment, the symptom scores were significantly improved. The changes of pulmonary function and arterial blood gas were significantly different from those in the control group (P <0.05), but there was no significant difference between the two groups. Compared with the control group, the FEV 1 No significant improvement (P> 0.05). Conclusion Budesonide solution inhalation of COPD patients with acute pulmonary infection can effectively improve the symptoms and quality of life, with good compliance and safety.